Sarepta Therapeutics (SRPT) to Release 3-Year EMBARK Study Results on Elevidys, Stock Up 10%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2026
0mins
Should l Buy SRPT?
Source: seekingalpha
- Results Announcement: Sarepta Therapeutics has announced it will release the three-year results from its EMBARK study on January 26, focusing on ambulatory Duchenne muscular dystrophy patients aged four to seven at treatment, which is expected to significantly impact the company's future market performance.
- Positive Market Reaction: Following this announcement, Sarepta's stock rose approximately 10% in after-hours trading, indicating strong investor anticipation for the upcoming data, which could influence future financing and partnership opportunities for the company.
- Webcast Scheduled: The company plans to hold a webcast and conference call at 8:30 AM ET on January 26 to further discuss the study results, providing investors with deeper insights that may affect stock price volatility.
- Market Expectations and Challenges: While there is optimism surrounding the upcoming results, previous preliminary findings did not meet market expectations, leading to cautious investor sentiment regarding Elevidys's future performance, which may impact the company's long-term strategic planning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to rise
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 18.590
Low
5.00
Averages
20.80
High
45.00
Current: 18.590
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regenxbio vs. Sarepta Patent Lawsuit Reinstated
- Lawsuit Reinstatement: The U.S. Court of Appeals has reinstated the patent lawsuit between Regenxbio and Sarepta regarding Sarepta's DMD treatment Elevidys, marking a new legal hurdle for Sarepta that could impact its market performance.
- Damages Request: Regenxbio and the University of Pennsylvania are seeking over $900 million in damages in the lawsuit, which could place significant financial pressure on Sarepta, especially amid ongoing regulatory scrutiny.
- Safety Concerns: Elevidys raised safety concerns in 2025 following the deaths of two patients, prompting Sarepta to develop a risk mitigation strategy to resume shipments to non-ambulatory patients, potentially affecting market confidence and sales forecasts.
- Market Sentiment: On Stocktwits, retail sentiment around RGNX and SRPT stocks trended bearish, with RGNX shares gaining 11% over the past year while SRPT stock plummeted 83%, reflecting market uncertainty regarding Sarepta's future prospects.
See More
Federal Appeals Court Reverses Sarepta's Patent Victory
- Patent Dispute Reversal: The U.S. Court of Appeals for the Federal Circuit overturned a Delaware federal court ruling favoring Sarepta in its patent dispute with Regenxbio, necessitating further proceedings that could impact Sarepta's market outlook for its Duchenne muscular dystrophy treatment, Elevidys.
- Patent Technology Context: The contested patent, 10,526,617, pertains to Regenxbio's adeno-associated virus gene delivery platform, with Regenxbio alleging that Sarepta's use of this patent in Elevidys production could expose Sarepta to legal and financial risks if the ruling is unfavorable.
- University Involvement: The University of Pennsylvania, as a co-plaintiff holding an exclusive license to the patent, underscores the importance of intellectual property protection in the biotech sector, potentially affecting future collaborations and technology transfers.
- Market Reaction Potential: This ruling may lead to stock price volatility for Regenxbio, especially in light of FDA scrutiny over its gene therapies, prompting investors to monitor the implications of the upcoming proceedings on both companies' stock valuations.
See More
Sarepta Therapeutics to Report Q4 and Full-Year 2025 Financial Results
- Earnings Report Schedule: Sarepta Therapeutics is set to release its fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on February 25, 2026, reflecting the company's ongoing commitment to precision genetic medicine.
- Conference Call Details: Following the earnings release, Sarepta will host a conference call at 4:30 p.m. E.T. to discuss the financial results, with participants required to register in advance to obtain dial-in information, ensuring smooth communication of key insights.
- Investor Relations Focus: The company emphasizes transparency by providing a live webcast of the event on its investor relations website, with a replay archived for one year post-event, highlighting its commitment to keeping investors informed.
- Company Mission: Sarepta is dedicated to engineering precision genetic medicine for rare diseases, holding a leadership position in Duchenne muscular dystrophy and showcasing a robust portfolio across muscle, central nervous system, and cardiac diseases.
See More
Sarepta Therapeutics Set to Release Financial Results for Q4 and Full Year 2025
- Company Announcement: Sarepta Therapeutics has announced its financial results for the fourth quarter and the full year of 2025.
- Financial Performance: The report includes key metrics and insights into the company's financial health and operational progress during the specified period.
See More
Sarepta Receives Approval for SRP-1005 Clinical Trial in New Zealand
- Clinical Trial Approval: Sarepta Therapeutics announced that Medsafe has approved its clinical trial application for SRP-1005, with the first-in-human trial expected to begin in Q2 2026, marking a significant advancement in the treatment of rare diseases.
- Study Design: The INSIGHTT study is a Phase 1, multi-center, dose escalation trial that plans to enroll approximately 24 participants to evaluate the safety and tolerability of SRP-1005, potentially providing a new treatment option for Huntington's disease patients and filling a market gap.
- Technological Innovation: SRP-1005 utilizes an advanced TfR1 approach with subcutaneous administration to avoid saturating the transferrin receptor, enabling efficient delivery to the central nervous system, indicating a potential breakthrough in treating neurodegenerative diseases.
- Market Potential: With about 40,000 symptomatic Huntington's disease patients and an additional 200,000 at risk in the U.S., the successful development of SRP-1005 could present significant market opportunities and revenue growth potential for Sarepta as demand for effective treatments increases.
See More
Analysis of Risks and Returns in Selling SRPT Options
- Options Selling Risk: Selling puts on SRPT does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, otherwise they only collect the premium.
- Market Price Impact: If Sarepta Therapeutics' shares do not decline by 26.4%, the put seller can only achieve a 22.2% annualized return, highlighting the asymmetric risk-reward profile of this options selling strategy.
- Volatility Analysis: With a trailing twelve-month volatility of 119% calculated from the last 251 trading days, this metric serves as a crucial reference for investors assessing the risk-reward of selling the January 2027 put at the $15 strike price.
- Market Strategy Recommendation: Investors should carefully evaluate whether selling SRPT puts under current market conditions is worthwhile, ensuring a reasonable alignment between risk and potential returns based on historical volatility and fundamental analysis.
See More
Regenxbio vs. Sarepta Patent Lawsuit Reinstated
- Lawsuit Reinstatement: The U.S. Court of Appeals has reinstated the patent lawsuit between Regenxbio and Sarepta regarding Sarepta's DMD treatment Elevidys, marking a new legal hurdle for Sarepta that could impact its market performance.
- Damages Request: Regenxbio and the University of Pennsylvania are seeking over $900 million in damages in the lawsuit, which could place significant financial pressure on Sarepta, especially amid ongoing regulatory scrutiny.
- Safety Concerns: Elevidys raised safety concerns in 2025 following the deaths of two patients, prompting Sarepta to develop a risk mitigation strategy to resume shipments to non-ambulatory patients, potentially affecting market confidence and sales forecasts.
- Market Sentiment: On Stocktwits, retail sentiment around RGNX and SRPT stocks trended bearish, with RGNX shares gaining 11% over the past year while SRPT stock plummeted 83%, reflecting market uncertainty regarding Sarepta's future prospects.
See More
Federal Appeals Court Reverses Sarepta's Patent Victory
- Patent Dispute Reversal: The U.S. Court of Appeals for the Federal Circuit overturned a Delaware federal court ruling favoring Sarepta in its patent dispute with Regenxbio, necessitating further proceedings that could impact Sarepta's market outlook for its Duchenne muscular dystrophy treatment, Elevidys.
- Patent Technology Context: The contested patent, 10,526,617, pertains to Regenxbio's adeno-associated virus gene delivery platform, with Regenxbio alleging that Sarepta's use of this patent in Elevidys production could expose Sarepta to legal and financial risks if the ruling is unfavorable.
- University Involvement: The University of Pennsylvania, as a co-plaintiff holding an exclusive license to the patent, underscores the importance of intellectual property protection in the biotech sector, potentially affecting future collaborations and technology transfers.
- Market Reaction Potential: This ruling may lead to stock price volatility for Regenxbio, especially in light of FDA scrutiny over its gene therapies, prompting investors to monitor the implications of the upcoming proceedings on both companies' stock valuations.
See More
Sarepta Therapeutics to Report Q4 and Full-Year 2025 Financial Results
- Earnings Report Schedule: Sarepta Therapeutics is set to release its fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on February 25, 2026, reflecting the company's ongoing commitment to precision genetic medicine.
- Conference Call Details: Following the earnings release, Sarepta will host a conference call at 4:30 p.m. E.T. to discuss the financial results, with participants required to register in advance to obtain dial-in information, ensuring smooth communication of key insights.
- Investor Relations Focus: The company emphasizes transparency by providing a live webcast of the event on its investor relations website, with a replay archived for one year post-event, highlighting its commitment to keeping investors informed.
- Company Mission: Sarepta is dedicated to engineering precision genetic medicine for rare diseases, holding a leadership position in Duchenne muscular dystrophy and showcasing a robust portfolio across muscle, central nervous system, and cardiac diseases.
See More
Sarepta Therapeutics Set to Release Financial Results for Q4 and Full Year 2025
- Company Announcement: Sarepta Therapeutics has announced its financial results for the fourth quarter and the full year of 2025.
- Financial Performance: The report includes key metrics and insights into the company's financial health and operational progress during the specified period.
See More
Sarepta Receives Approval for SRP-1005 Clinical Trial in New Zealand
- Clinical Trial Approval: Sarepta Therapeutics announced that Medsafe has approved its clinical trial application for SRP-1005, with the first-in-human trial expected to begin in Q2 2026, marking a significant advancement in the treatment of rare diseases.
- Study Design: The INSIGHTT study is a Phase 1, multi-center, dose escalation trial that plans to enroll approximately 24 participants to evaluate the safety and tolerability of SRP-1005, potentially providing a new treatment option for Huntington's disease patients and filling a market gap.
- Technological Innovation: SRP-1005 utilizes an advanced TfR1 approach with subcutaneous administration to avoid saturating the transferrin receptor, enabling efficient delivery to the central nervous system, indicating a potential breakthrough in treating neurodegenerative diseases.
- Market Potential: With about 40,000 symptomatic Huntington's disease patients and an additional 200,000 at risk in the U.S., the successful development of SRP-1005 could present significant market opportunities and revenue growth potential for Sarepta as demand for effective treatments increases.
See More
Analysis of Risks and Returns in Selling SRPT Options
- Options Selling Risk: Selling puts on SRPT does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, otherwise they only collect the premium.
- Market Price Impact: If Sarepta Therapeutics' shares do not decline by 26.4%, the put seller can only achieve a 22.2% annualized return, highlighting the asymmetric risk-reward profile of this options selling strategy.
- Volatility Analysis: With a trailing twelve-month volatility of 119% calculated from the last 251 trading days, this metric serves as a crucial reference for investors assessing the risk-reward of selling the January 2027 put at the $15 strike price.
- Market Strategy Recommendation: Investors should carefully evaluate whether selling SRPT puts under current market conditions is worthwhile, ensuring a reasonable alignment between risk and potential returns based on historical volatility and fundamental analysis.
See More
